InvestorsHub Logo
Followers 87
Posts 33424
Boards Moderated 87
Alias Born 03/22/2005

Re: None

Friday, 03/31/2023 2:48:40 PM

Friday, March 31, 2023 2:48:40 PM

Post# of 526
Thermo Fisher Scientific (TMO) - >>> An important player in the field of laboratory research.


https://finance.yahoo.com/news/end-bear-market-may-sight-204211341.html


Thermo Fisher is a maker and supplier of laboratory equipment – scientific instruments, chemicals and reagents, sampling and testing supplies, and even lab-related software systems. Thermo Fisher works with a broad customer base, serving any clients in any field involving lab work; the company frequently deals with academics, medical researchers, and government entities.

While Thermo Fisher occupies a highly particular niche, supplying research labs has been profitable in the post-pandemic world. The company’s 4Q22 results saw both the top and bottom line beat expectations, even if they did not expand year-over-year. At the top line, the quarterly revenue of $11.45 billion was a full $1.04 billion above the forecast, while at the bottom line the non-GAAP EPS of $5.40 was 20 cents ahead of consensus estimates.

Thermo Fisher caught the eye of Morgan Stanley analyst Tejas Savant who writes: “We like TMO for the breadth of its portfolio, diversified customer base and scale – attributes that we believe will prove advantageous in navigating a potential recession, in addition to inflationary pressures and geopolitical uncertainty. TMO’s favorable end market exposure, PPI business system, and track record of consistent all-weather execution underpin our confidence in management’s long-term core organic growth target of 7- 9% with mid-teens EPS growth.”

Unsurprisingly, Savant rates TMO shares an Overweight (i.e. Buy), while his $670 suggests the stock will grow 19% in the year ahead. (To watch Savant’s track record, click here)

Overall, this stock has picked up 14 recent analyst reviews, and these include 12 Buys that overbalance 1 Hold and 1 Sell for a Strong Buy consensus rating. The stock’s average price target of $656.71 implies ~17% one-year gain from the current share price of $561.69.

<<<



---
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.